Objective Placenta accreta is clinically associated with maternal uterine scar. Our objective was to investigate the biochemical contribution of maternal scarring to hyperinvasive trophoblast. We hypothesised that trophoblast over-invasion in placenta accreta is associated with aberrant invasion-site signalling of growth and angiogenic factors known to be involved in wound healing and promotion of cell invasion through the epithelial to mesenchymal cellular programme.
Introduction
Placenta accreta spectrum disorders occur when trophoblast cells abnormally attach to and invade maternal myometrium. Although the clinical risk factors of uterine scar and placenta praevia are known, the biochemical mechanisms responsible for increased trophoblast invasiveness remain elusive. [1] [2] [3] [4] [5] Extravillous trophoblast (EVT) invade into, but not beyond, maternal decidua and blood vessels, replacing endothelium, in the late first and early second trimester. This process is facilitated by a physiologic cellular programme called the epithelial-to-mesenchymal transition (EMT). 6, 7 Our group reported that in accreta, EVT remains in a persistent state of hyperinvasiveness due to EMT, suggesting a cause of excessive myometrial invasion. 8, 9 Additionally, we reported that pro-angiogenic vascular endothelial growth factor (VEGF) prominently stained EVT cells in placenta accreta specimens. 9 Both wound healing and angiogenesis utilise EMT programming. 10, 11 We hypothesised that in accreta, the maternal invasion site may contain local aberrations promoting persistent EMT. Our objective in this study was to investigate further the roles of angiogenic and growth factors implicated in EMT, specifically the endoglin-TGFb system as well as regulators of VEGF, in placenta accreta.
Materials and methods

Patient population and serum samples
In a cross-sectional study design, we analysed maternal tissue and blood serum samples from women enrolled at Yale-New Haven Hospital between May 2005 and July 2011. Figure S1 describes our study populations. Our study group consisted of 16 consecutive women who had antenatally suspected invasive placentation based on grey-scale and colour Doppler sonography. Of these, blood and tissue samples were retrieved prospectively on 15 patients. In one patient we could obtain only maternal blood due to study staff logistics prohibiting tissue collection at the time of delivery. This population is described in the centre row of Figure S1 . Of women with abnormal invasion, two had placenta accreta, ten had placenta increta (nine with available tissue) and four had placenta percreta, all confirmed by inspection of the hysterectomy specimens by a pathologist.
For comparison, tissues were retrieved from six women who had an uncomplicated gestation and repeat elective caesarean deliveries at term. Further description of these control samples are described in the centre column of Figure S1 .
Maternal blood samples (n = 25) was collected during the second and third trimester from women with placenta accreta, normal pregnancy and placenta praevia as represented in the right-hand column of Figure S1 . Because many of our accreta patients had placenta praevia, to rule out confounding, changes in maternal levels of our analytes were compared with those of women with placenta praevia-absent over-invasion. All blood specimens were retrieved prior to steroid administration or blood transfusion. All women provided signed informed consent under protocols approved by the Human Investigation Committee of Yale University.
Core outcomes for this study were differences in immunohistological staining patterns for individual angiogenic and growth factors selected between accreta and control populations. We then investigated differences in serum protein expression for the same factors, seeking to determine whether any of them may have clinical relevance as systemic biomarkers for placenta accreta. All patients recruited for this study understood that their contributions were de-identified and collected for the purpose of advancement of translational science.
Histology and immunohistochemistry
Tissue biopsies were collected immediately after delivery. Tissues were formalin-fixed for 24 hours, paraffinembedded, and cut as serial sections at 5 lm thickness. Sections were immunostained for Masson Trichrome (to distinguish cells from connective tissue; Richard-Allan Scientific, Kalamazoo, MI, USA), TGFb1 (an inhibitor of invasion, 1:100; Novus Biologicals, Littleton, CO, USA), TGFb2 (a promoter of invasion, 1:500; Novus Biologicals), TGFb3 (an inhibitor of invasion, 1:100; Novus Biologicals), endoglin (Eng, an anti-angiogenic marker, 1:100; BD Biosciences, Bedford, MA, USA), matrix metalloproteinase 14 (MMP-14, cleavage protein for endoglin, 1:500; R&D Systems, Minneapolis, MN, USA), VEGF (1:100; Abcam Inc., Cambridge, MA, USA), endostatin (anti-angiogenic collagen modulator of VEGF, 1:100; R&D Systems), hypoxia-inducible factor-1a (HIF-1a, pro-angiogenic modulator of VEGF, 1:1000; Abcam Inc.) and cytokeratin-7 (CK7, marker of EVT, 1:100; Invitrogen Co., Camarillo, CA, USA). Specimens were stained in a single batch per antibody to assure uniformity. Histological scores were assigned by two independent investigators, one of whom was blinded to specimen type, visualising three representative areas from each slide selected by the unblinded investigator. Strength of nuclear, cytoplasmic, membranous and extracellular staining was quantified using standardised semiquantitative histological scoring (H-score) on a 0-3 scale based on intensity of staining for myometrial cells, villous cytotrophoblast, interstitial extravillous trophoblast and decidua.
Blood collection, storage
Blood was collected prospectively during an office visit or at the time of admission for vaginal bleeding. Samples were retrieved and processed as previously described. 8, 9 Immunoassay ELISA assays for soluble human Eng (sEng), endostatin and HIF-1a were performed to measure their levels in maternal serum, according to the manufacturers' instructions (R&D Systems for sEng and endostatin; Abcam Inc. for sHIF-1a). Samples were diluted 1:10 for sEng, 1:50 for soluble endostatin (sES), and both 1:10 and 1:2 for sHIF1a to fall within the range of the standard curves. The interassay and intra-assay coefficient of variation was <10%.
Statistical analysis
Data were tested for normality (Shapiro-Wilk test) and reported as median and interquartile range (IQR) or mean AE standard error of the mean (SEM), as appropriate. Data were analysed using Mann-Whitney Rank Sum test, Kruskal-Wallis one-way analysis of variance (ANOVA) and Chi-square tests. A P < 0.05 was considered significant. Data analysis was performed with SIGMA STAT, version 12.5 (RockWare, Golden, CO, USA).
Results
Demographic and clinical characteristics
In Table 1 we present the demographic and clinical data for the maternal serum experiments. Women with invasive placentation and praevia were significantly older and had higher gravidity than pregnant controls. Women with accreta had significantly higher numbers of previous caesarean deliveries compared with all other groups. By study design, the pregnant control (P-CRL) group was enrolled at an earlier gestational age (GA) to develop a longitudinal trend for analyte levels throughout pregnancy. Among women with invasive placentation, the incidence of placenta praevia was 81% (13/16). These two groups of women were more likely to have a bleeding complication than those with normal gestations. GA at delivery was significantly lower for patients with invasive placentation and praevia relative to controls, with anticipated increased frequencies of caesarean in praevia and accreta patients, and hysterectomy in accreta patients. Demographic and clinical data statistics are not reported for histological controls due to small numbers; however, maternal age [28.5 years (range 21-38)] was younger for caesarean controls than for accreta samples with comparable gravidity Histologic immunoreactivity in normal and invasive placenta Figure 1 demonstrates the results of our histological staining for angiogenic markers and their regulatory proteins, comparing maternal placental invasion site in accreta and in normal bed biopsy. Placenta accreta EVTs ( Figure 1A ), compared with bed biopsies ( Figure 1G ), showed higher anti-angiogenic Eng surface staining, as well as increased intervillous space sEng staining, implying increased shedding of the extracellular domain. Increased cell surface and cytoplasmic of the cleavage protein MMP-14 staining was also appreciated in EVTs of cases with excessive placental invasion ( Figure 1B ) compared to normal placental bed biopsies ( Figure 1H ). VEGF regulators endostatin and HIF1a, as well as VEGF itself, was compared in women with accreta ( Figure 1C -E) or normal implantation ( Figure 1I -K). The CK7 marker was used to identify presence of EVT at the site of placental invasion ( Figure 1F ) in both accreta and placental bed biopsy specimens ( Figure 1L ). At the site of excessive trophoblast invasion, accreta tissues were virtually without immunostaining for either endostatin or HIF1a relative to normal term placental bed biopsies. Decidual cells strongly demonstrated HIF-1a, as demonstrated in Figure 1 (J) inset panel. In a contrasting pattern, VEGF was abundantly expressed in EVT at the site of excessive myometrial invasion, significantly beyond staining observed in normal placental bed biopsies. H-score quantification ( Figure 1M ) confirmed our histological observations were not different between the two scoring investigators and were not correlated with extremes in gestational ages. Placenta praevia samples did not differ from normal pregnancy (data not shown). Figure S2 displays immunostaining for TGFb proteins in EVTs of abnormal placenta and placental bed biopsy. Our microscopic evaluation of the tissue staining, supported by the H-scores quantification, demonstrated that EVT staining for TGFb1, -b2, and -b3 proteins did not differ between normal and abnormal samples. EVTs of abnormally and normally invaded tissues abundantly expressed TGFb1, -b2 and -b3.
In Figure 2 we present the relation between maternal collagen and TGFb1 staining at the point of invasion in women with invasive placentation. For comparison, we used placental bed biopsy, unscarred control pregnant myometrium, unscarred myometrium from accreta cases from sites remote from placental invasion (data not shown but comparable with control pregnant myometrium) and non-pregnant women. Masson Trichrome staining was used to differentiate myometrium (pink) from collagen bundles and extracellular matrix (blue). The invasive placental specimens demonstrated that contrary to generally accepted definitions, accreta trophoblast invades a collagen matrix near the myometrium (Figure 2A) , rather than interdigitating with myometrial cells. Placental bed biopsy ( Figure 2B ) has relatively less collagen and increased cellularity in normal decidua. Both unscarred pregnant (Figure 2C ) and non-pregnant ( Figure 2D ) reference samples demonstrate normal collagen surrounding myometrial bundles in the absence of EVTs. Myometrial cells and decidua stained uniformly for TGFb1 ( Figure 2E-H) . However, the collagen bundles into which the abnormal trophoblast invaded demonstrated near-absence of TGFb1 staining in the areas heavily populated by EVTs ( Figure 2E ). Areas of biopsy of unscarred myometrium ( Figure 2G ) and nonpregnant myometrium (Figure 2H ) similarly demonstrated a paucity of TGFb1 staining in collagen bundles. TGFb2 and TGFb3 collagen and myometrial staining did not demonstrate relevant differences.
A schematic representation of the interpretations of our histologic findings is presented in Figure 3 .
Circulating soluble factors by ELISA ( Figure S3) In women with normal pregnancy outcomes, there was a significant correlation between maternal serum levels of sEng and GA (r = 0.779, P < 0.001). First and second trimester normal maternal circulatory levels of sEng were unchanged, followed by a significant increase in the third trimester (P < 0.001). Among women with invasive placentation there was no significant difference in serum sEng when classified by degree of invasion. However, when normalised for GA, women with invasive placentation had lower serum levels of sEng compared with both women with normal placentation and women with placenta praevia alone (P < 0.05 for both).
Systemic soluble endostatin levels were unaffected by increasing GA (r = 0.135, P = 0.434) or when grouped by trimester (P = 0.370). There was no significant difference in sES concentration based on the histological degree of invasion (P = 0.094). Even after correction for GA, sES concentration was not different from that observed in women with normal pregnancy or in women with praevia alone (P = 0.710). Immunoreactivity for HIF-1a was undetectable in serum (or plasma) of pregnant or non-pregnant women by either ELISA or Western blot (data not shown).
Discussion
Main findings
We demonstrate significant differences in angiogenic and growth factors at the point of placental invasion in women with abnormally invasive placentation. Increased intervillous staining for Eng in placenta accreta implies processing and entrapment of Eng at the site of trophoblast invasion. This assertion is supported by increased membrane staining of MMP-14, which suggests increased cleavage of Eng. 12, 13 Eng, a ligand of the TGFb receptor, is anti-angiogenic and its loss is linked to increased invasive ability of EVT. 14, 15 Increased Eng shedding has also been linked with deregulation of TGFb signalling. 15, 16 We formerly demonstrated that VEGF is trapped within the placental lakes characteristic of accreta. 9 VEGF is pro-angiogenic, and we theorise that the increased tissue staining of the Eng at the accreta site is a local attempt to balance the process of placental vascular remodelling. The observed decrease in maternal serum sEng levels in accreta, compared with physiologic pregnancy, implies that in accreta, Eng may be trapped locally from maternal circulation.
We demonstrate that HIF-1a, which is implicated in VEGF upregulation in first trimester trophoblast invasion, 17 is abundantly present in decidual cells of normal tissues, but absent in invasive samples. This finding suggests the excessive EVT invasion and overexpression of VEGF in accreta is not driven by relative hypoxia in the uterine scar. Rather, it may suggest that absence of decidual signals impact placentation. Endostatin, a VEGF-inhibiting collagen fragment, is also normally expressed in the placental villous basement membrane and decidual stromal cells. 18 The absence of endostatin at the area of excessive invasion, and abundantly surrounding EVT in normal samples, serves to suggest that collagen and extracellular matrix in maternal uterine scar itself play an important role in placentation. These findings suggest the importance of both absence of decidua and presence of maternal scar in promoting trophoblast invasiveness.
TGFb regulates cell proliferation and differentiation, embryo development, wound healing and angiogenesis. 17, 19, 20 We show that TGFb proteins are expressed by EVT, a fetal-derived driver of placental invasion. We also demonstrate inhibitory TGFb1 presence in decidual cells, which under normal circumstances may provide a 'stop signal' for EVT. We demonstrate a lack of this inhibition in the maternal collagen surrounding accreta EVTs, again suggesting that both absence of decidua and presence of a collagen matrix at the invasion site are important in accreta formation. An imbalance of TGFb in the scarred maternal compartment could provide a scar-based EMT signal responsible for promoting the continued hyperinvasive phenotype of accreta EVTs.
Strengths and limitations
The unique invasive characteristics of the human placenta, coupled with the surgical scarring which drives placenta accreta formation, make generation of an animal model difficult for validation of our hypothesis in vivo. By this token, our study is observational in nature. Despite this limitation, we feel the strength of our study is the review of a large number of tissue specimens, given the rarity of this disease. We feel that translational observation is an essential first step to understand the pathophysiology of accreta, in order to design future in vitro studies. Our findings contribute to the literature to date attempting to elucidate the underlying pathology of this emerging disease.
Interpretation
Eng has received attention in the obstetric literature not for placenta accreta but as a marker of pre-eclampsia. 13 Preeclampsia is characterised by poor placental invasion and, as such, Eng may be an important marker of deviant EVT invasiveness. Collectively, our data suggest that mediators of angiogenesis and vascular invasion are unable to achieve appropriate homeostasis in placenta accreta due to features specific to the local environment. Based on these studies, we infer that angiogenic dysregulation contributes to pathological placental invasion.
Aberrant signalling and TGFb1 overexpression have been shown to initiate EMT in tumour invasion and cancer metastasis. 11, 19 EMT is a normal phenomenon characterised by modulation of cell proliferation, adhesion, mobility and invasiveness. [20] [21] [22] It is critical to embryogenesis and placental formation. 7, 17 TGFb proteins have been shown to modulate trophoblasts along the invasive pathway, with TGFb2 increasing invasion and TGFb1 and TGFb3 inhibiting invasion. 17, 23, 24 As EMT is also a key feature of wound healing and fibrosis, it is likely an active process within scar tissue, including post-caesarean uterine scar. Based on our data, we speculate that EMT occurring in an incompletely healed myometrial or endometrial scar may provide an extracellular matrix on which placental invasion becomes dysregulated. As Eng is a ligand of the TGFb system, this may also provide a link between EMT transformation and dyregulated angiogenesis.
Conclusion
We demonstrate that the Eng-TGFb system is differentially expressed at the placental invasion site in accreta. We establish dysregulation of angiogenic signalling by Eng, and VEGF related both to absence of decidua and presence of collagen matrix. Our translational data also suggest that components of the maternal environment, specifically TGFb1, may influence and increase invasiveness of placental cells, providing insight into the role of a previous , unscarred pregnant myometrium (C); and nonpregnant myometrium (3D). Extravillous trophoblasts were seen to invade a collagen bundle, rather than between myometrial cells (A). Myometrial TGFb1 was near-absent in the collagen bundles heavily populated by dark-staining extravillous trophoblasts (E). Placental bed biopsy had a notable lack of collagen bundles, but decidual cells (dc) were present that did stain lightly for TGFb1 (F). Absence of TGFb1 was also seen in collagen in normal myometrial samples (G,H). Myometrium was seen to stain uniformly for TGFb1 in invasive and normal myometrial samples (E-H).
caesarean scar in placenta accreta pathology. Further mechanistic studies are indicated to compare EMT signals in normal and abnormal uterine scar, with a goal to promote scar optimisation and avoid complications in future pregnancies.
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